Metabolon, Inc. has announced the signing of a contract supporting the US Army Medical Research Institute of Infectious Diseases (USAMRIID).
The collaboration uses Metabolon’s proprietary metabolomics platform to study the biochemical profiles of humans given the AVA anthrax vaccine. The AVA vaccine is the only FDA-licensed anthrax vaccine for humans.
“This collaboration represents the first large-scale metabolomics study of human subjects given a vaccine,” said Mike Milburn, Metabolon’s Chief Scientific Officer. “This type of comprehensive biochemical profiling will help USAMRIID better understand the vaccine’s safety, efficacy, and mechanism of action.”